Mark is an EIR and was formerly a founding employee and CTO of Matchpoint Therapeutics. He was also Co-Founder and CTO of Quench Bio and before that was VP, Head of Drug Discovery at Quartet Medicine. Mark has >29 years of experience in drug discovery and development and is a co-inventor of Incivek (Telaprevir), an HCV protease inhibitor. He was previously VP of Medicinal and Computational Chemistry at Forma Therapeutics where he focused on small molecule cancer therapeutics. Prior to that, Mark held positions of increasing responsibility during his 16-year career at Eli Lilly including head of chemistry and Global Head of Operations for the discovery chemistry group. He obtained his Ph.D. in organic chemistry from Stanford University and his undergraduate degree from the University of Notre Dame.